ALK and adenocarcinoma: The results indicated that the EML4-ALK fusion frequency is higher in the adenocarcinoma group than in the non-adenocarcinoma group (11.2% vs 3.3%, RR = 2.30, 95%CI, 1.60–3.31, P<0.01) in Fig. 2B.